While many insurance plans and employers are willing to cover GLP-1 medications for treating type 2 diabetes, coverage for obesity treatment is less common
Beyond visual checks, the most reliable indicator is efficacy, if appetite suppression diminishes or weight loss stalls unexpectedly mid-protocol, a degraded vial is a possible cause
It's a simple, elegant solution to a complex biochemical problem
Akkermansia muciniphila, a probiotic strain, is gaining appeal for positively impacting metabolic function
Despite these limitations, the FDA database offers real-world data on clinically relevant adverse events associated with medication use, broadening the pharmacovigilance landscape
They are not effective, have little scientific evidence to back up their claims, and are misleading because they do not contain any GLP-1 agonists